AbbVie (ABBV) Current Assets (2012 - 2026)

AbbVie has disclosed Current Assets across 15 years of filings, most recently posting $33.5 billion for Q1 2026.

• In Q1 2026, Current Assets rose 21.15% year-over-year to $33.5 billion; the TTM figure through Mar 2026 stood at $33.5 billion (up 21.15% YoY), while the FY2025 annual figure was $29.1 billion, up 13.6% from the prior year.
• Current Assets rose to $33.5 billion in Q1 2026, from $29.1 billion in the prior quarter.
• Over the last five years, Current Assets for ABBV reached as high as $38.9 billion in Q1 2024 and fell as low as $25.6 billion in Q4 2024.
• The 5-year median for Current Assets is $29.1 billion (2025), against an average of $30.0 billion.
• Annual changes were most pronounced in 2024 — Current Assets jumped 46.75% — and 2025, when it decreased 28.8%.
• A 5-year view of Current Assets shows it stood at $28.5 billion in 2022, then grew by 15.95% to $33.0 billion in 2023, then retreated by 22.48% to $25.6 billion in 2024, then increased by 13.6% to $29.1 billion in 2025, then rose by 15.37% to $33.5 billion in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $33.5 billion, $29.1 billion, and $28.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.